Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has rejected Epix Pharmaceutical's appeal to approve its novel blood pool imaging agent Vasovist. A request for an advisory committee to review Vasovist was also turned down.
Subscribe to our email newsletter
Epix submitted the appeal to the FDA’s Office of New Drugs (OND) on June 30, 2006 in response to two prior approvable letters for Vasovist. Epix were also told by the FDA that conducting two new clinical trials would be needed if they were going to secure a third approval and would be safer than using data from a previous clinical trial.
“We are evaluating several options available to us as next steps with Vasovist in the US, including the option to appeal this decision to the next level at the FDA, and will update the market accordingly,” said Andrew Uprichard President of Epix Pharmaceuticals.
Vasovist was approved in the European Union and Switzerland last year. Vasovist has also been recommended for approval in Australia.